Q-omics provides the consensus-scored IL9RP3 profile across patient tissues and cancer cell-line models. IL9RP3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, IL9RP3 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, IL9RP3 RNA expression shows 15,953 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KIRC, and UVM as cancer lineages where IL9RP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL9RP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL9RP3 survival associations across molecular data types. IL9RP3 RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL9RP3 RNA expression–survival associations across cancer types. High IL9RP3 expression shows unfavorable associations in KIRC, COAD, PRAD and MESO, but favorable associations in BLCA and UCS. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for IL9RP3 RNA expression.
This table summarizes IL9RP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for IL9RP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL9RP3 shows higher tumor expression in KIRC, KIRP, KICH, BRCA, CHOL and COAD. The KIRC box plot shows higher IL9RP3 RNA expression in tumor versus normal tissue (log2 FC = +0.194, t-test p < 0.001).
This table shows molecular features associated with IL9RP3 in patient tissues and cancer cell lines. In patient samples, IL9RP3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
